Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 304Stomach Neoplasms 34Neoplasm Metastasis 24Neoplasms 16Colorectal Neoplasms 16Breast Neoplasms, Male 16HER2-positive Breast Cancer 11Inflammatory Breast Neoplasms 10Triple Negative Breast Neoplasms 9Esophageal Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Rectal Neoplasms 7Adenocarcinoma 7Colonic Neoplasms 6Urinary Bladder Neoplasms 5Pathologic Complete Response 5Biliary Tract Neoplasms 5Urologic Neoplasms 4Salivary Gland Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ductal, Breast 4Recurrence 3Pancreatic Neoplasms 3Neoplastic Cells, Circulating 3Multiple Myeloma 3Meningeal Neoplasms 3HER2-positive Gastric Cancer 3

Interventions

Oxaliplatin 3Radiotherapy 2Folfox protocol 2Fluorouracil 2Capecitabine 2Bevacizumab 2Artesunate 2camrelizumab 1apatinib 1alectinib 1XELOX 1Trastuzumab 1Ocoxin 1Leucovorin 1Irinotecan 1Drug Therapy 1Chemoradiotherapy 1ABT-165 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Intestinal Neoplasms × Trastuzumab × Clear all
NCT05193292 2022-01-14

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Fudan University

Phase 2 Unknown
77 enrolled
Gastrointestinal

Intestinal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡